In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.
Sant P. Chawla, MD
Advertisement
Articles by Sant P. Chawla, MD
Advertisement
Latest Updated Articles
Aldoxorubicin Shows Promise in Advanced Soft-Tissue SarcomaPublished: July 22nd 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels
2
FDA Approves Updated Cosibelimab Label in Cutaneous Squamous Cell Carcinoma
3
Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer
4
A Decline in the US Oncology Workforce: What Will the Next Decade Bring?
5
